RARE Quote, Financials, Valuation and Earnings

Cormedix has a net margin of -108.46% compared to Ultragenyx Pharmaceutical's net margin of 52.82%. Ultragenyx Pharmaceutical's return on equity of -205.06% beat Cormedix's return on equity of 23.7%.

Ultragenyx Pharmaceutical has a consensus price target of $87.21, signalling upside risk potential of 219.34%. On the other hand Cormedix has an analysts' consensus of $19.00 which suggests that it could grow by 70.71%. Given that Ultragenyx Pharmaceutical has higher upside potential than Cormedix, analysts believe Ultragenyx Pharmaceutical is more attractive than Cormedix.

Ultragenyx Pharmaceutical has a beta of 0.261, which suggesting that the stock is 73.884% less volatile than S&P 500. In comparison Cormedix has a beta of 1.581, suggesting its more volatile than the S&P 500 by 58.146%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.3M, which are larger than Cormedix quarterly revenues of $39.1M. Ultragenyx Pharmaceutical's net income of -$151.1M is lower than Cormedix's net income of $20.6M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Cormedix's PE ratio is 50.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 4.32x versus 8.32x for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech has a net margin of -108.46% compared to Ultragenyx Pharmaceutical's net margin of -80.55%. Ultragenyx Pharmaceutical's return on equity of -205.06% beat Fortress Biotech's return on equity of --.

Ultragenyx Pharmaceutical has a consensus price target of $87.21, signalling upside risk potential of 219.34%. On the other hand Fortress Biotech has an analysts' consensus of $10.00 which suggests that it could grow by 407.61%. Given that Fortress Biotech has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Fortress Biotech is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.261, which suggesting that the stock is 73.884% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.752, suggesting its more volatile than the S&P 500 by 75.204%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.3M, which are larger than Fortress Biotech quarterly revenues of $13.1M. Ultragenyx Pharmaceutical's net income of -$151.1M is lower than Fortress Biotech's net income of -$10.6M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 4.32x versus 0.77x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of -108.46% compared to Ultragenyx Pharmaceutical's net margin of -17.31%. Ultragenyx Pharmaceutical's return on equity of -205.06% beat Amicus Therapeutics's return on equity of -17.7%.

Ultragenyx Pharmaceutical has a consensus price target of $87.21, signalling upside risk potential of 219.34%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 160.6%. Given that Ultragenyx Pharmaceutical has higher upside potential than Amicus Therapeutics, analysts believe Ultragenyx Pharmaceutical is more attractive than Amicus Therapeutics.

Ultragenyx Pharmaceutical has a beta of 0.261, which suggesting that the stock is 73.884% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.508, suggesting its less volatile than the S&P 500 by 49.181%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.3M, which are larger than Amicus Therapeutics quarterly revenues of $125.2M. Ultragenyx Pharmaceutical's net income of -$151.1M is lower than Amicus Therapeutics's net income of -$21.7M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 4.32x versus 3.42x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ligand Pharmaceuticals has a net margin of -108.46% compared to Ultragenyx Pharmaceutical's net margin of -93.64%. Ultragenyx Pharmaceutical's return on equity of -205.06% beat Ligand Pharmaceuticals's return on equity of -16.38%.

Ultragenyx Pharmaceutical has a consensus price target of $87.21, signalling upside risk potential of 219.34%. On the other hand Ligand Pharmaceuticals has an analysts' consensus of $143.88 which suggests that it could grow by 10.99%. Given that Ultragenyx Pharmaceutical has higher upside potential than Ligand Pharmaceuticals, analysts believe Ultragenyx Pharmaceutical is more attractive than Ligand Pharmaceuticals.

Ultragenyx Pharmaceutical has a beta of 0.261, which suggesting that the stock is 73.884% less volatile than S&P 500. In comparison Ligand Pharmaceuticals has a beta of 0.874, suggesting its less volatile than the S&P 500 by 12.628%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Ligand Pharmaceuticals pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.3M, which are larger than Ligand Pharmaceuticals quarterly revenues of $45.3M. Ultragenyx Pharmaceutical's net income of -$151.1M is lower than Ligand Pharmaceuticals's net income of -$42.5M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Ligand Pharmaceuticals's PE ratio is 46.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 4.32x versus 13.32x for Ligand Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.